108 bioequivalence tests approved by KFDA in first half

Published: 2012-09-28 06:57:00

Updated: 2012-09-28 06:57:00

The Korea Food and Drug Administration said Wednesday that it approved a total of 108 bioequivalence tests in the first half of this year, showing a decrease compared to 114 cases from a year earlier.

By therapeutic category, antihypertensive agents, such as Novartis’s Exforge (valsartan+amlop...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK